GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery. Founded by Hyo Min Park, Kunwoo Lee, and Niren Murthy in 2016GenEdit is backed by Sequoia Capital, Eli Lilly, Korea Investment Partners, CITRIS Foundry, and KB Investment and is headquartered in South San Francisco.